Back to Search Start Over

Mental Disorders in Young Adults from Families with the Presenilin-1 Gene Mutation E280A in the Preclinical Stage of Alzheimer's Disease.

Authors :
Villalba AC
García J
Ramos C
Cuastumal AR
Aguillón D
Aguirre-Acevedo DC
Madrigal L
Lopera F
Source :
Journal of Alzheimer's disease reports [J Alzheimers Dis Rep] 2019 Aug 29; Vol. 3 (1), pp. 241-250. Date of Electronic Publication: 2019 Aug 29.
Publication Year :
2019

Abstract

Background: There are forms of Alzheimer's disease (AD) that have an autosomal dominant inheritance pattern; one of them is caused by the E280A mutation in the gene that codes for Presenilin-1 ( PSEN1 ). Studying families of people with this mutation allows the evaluation of characteristics of the subjects before cognitive decline begins.<br />Objective: To determine whether having the mutation E280A in PSEN1 increases the risk of presenting mental disorders in adults under 30 years old who are in the preclinical stage of AD and may be eligible for primary prevention studies of AD.<br />Methods: A psychiatric evaluation was made to 120 people belonging to families with a history of early onset AD. Of these, 62 carried the E280A mutation in PSEN1 . The occurrence of mental disorders between carriers and non-carriers of the mutation was compared.<br />Results: No statistically significant differences were found in the frequency of any mental disorder between the group of carriers and non-carriers of the mutation (Hazard Ratio: 0.80, 95% CI 0.49 to 1.31); nor were differences observed when evaluating specific disorders.<br />Conclusion: The E280A mutation does not increase the risk of mental disorders before the age of 30 in the relatives of people affected by familial AD. Studies with larger sample sizes are required to assess the risk of low incidence mental disorders.<br />Competing Interests: A. Villalba, J. García, R. Cuastumal and D.C. Aguirre have nothing to disclosure. C. Ramos reports the following (pertinent for the last two years): grant and contract support from the NIA, Genentech/Roche, and an anonymous foundation to develop the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease - API ADAD - Registry since 2015 and she helps to conduct the API ADAD Trial in Colombia. D. Aguillón reports the following (pertinent for the last two years): grant and contract support from the National Institute on Aging - NIA -, Genentech/Roche, and an anonymous foundation to develop the API ADAD Registry since 2017 and he helps to conduct the API ADAD Trial in Colombia. L. Madrigal receives grant and contract support from the NIA, Genentech/Roche, and an anonymous foundation to develop the API ADAD Registry since 2013 and she helps to conduct the API ADAD Trial in Colombia. F. Lopera receives grand and contract support from the NIA, Genentech/Roche, and an anonymous foundation to develop the API ADAD Registry since 2013 and he is the principal investigator of the API ADAD Trial in Colombia.<br /> (© 2019 – IOS Press and the authors. All rights reserved.)

Details

Language :
English
ISSN :
2542-4823
Volume :
3
Issue :
1
Database :
MEDLINE
Journal :
Journal of Alzheimer's disease reports
Publication Type :
Academic Journal
Accession number :
31754656
Full Text :
https://doi.org/10.3233/ADR-190139